Pricing Log in Create free account
Saturday 17 October 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 31.2% and free cash flow grew 43.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

135.71 1.24 −0.91%
Market cap
$13.9B
P/E
19.2×
Fwd P/E
30.5×
Dividend yield
—
F-score
7/9
Altman Z
7.80
Beneish M
−2.64
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Neurocrine Biosciences, Inc. (NBIX) Business Profile

Updated before January 2025

Company Overview

Neurocrine Biosciences, Inc. (NBIX) is a leading biopharmaceutical company headquartered in San Diego, California. Founded in 1992, the company has established itself as a pioneer in developing innovative treatments for neurological, endocrine, and psychiatric disorders. Neurocrine’s mission is to relieve patient suffering and enhance lives through groundbreaking science and medicine. The company went public in 1996 and trades on the NASDAQ under the ticker symbol NBIX.

The leadership team at Neurocrine Biosciences is composed of seasoned professionals with extensive experience in the pharmaceutical and biotechnology industries. Kevin Gorman, Ph.D., serves as the Chief Executive Officer, bringing decades of expertise in drug development and corporate strategy. Other key executives include Matt Abernethy, Chief Financial Officer, and Eiry W. Roberts, M.D., Chief Medical Officer, who oversees the company’s clinical development programs.

Core Business Segments

Neurocrine Biosciences focuses on developing and commercializing treatments for complex and underserved medical conditions. The company’s core business segments include:

Neurological Disorders

Neurocrine is best known for its flagship product, INGREZZA® (valbenazine), which is approved for the treatment of tardive dyskinesia (TD), a neurological disorder characterized by involuntary movements. INGREZZA has become a market leader in this category, addressing a significant unmet medical need.

Endocrine Disorders

The company also offers ORILISSA® (elagolix) and ORIAHNN®, developed in collaboration with AbbVie, for the treatment of endometriosis and uterine fibroids, respectively. These products target hormonal pathways to alleviate symptoms and improve quality of life for patients.

Psychiatric Disorders

Neurocrine is actively developing treatments for psychiatric conditions, including bipolar disorder and schizophrenia. The company’s pipeline includes Luvadaxistat and other investigational therapies aimed at addressing cognitive and mood disorders.

Rare Diseases

Neurocrine is expanding its portfolio to include treatments for rare diseases, such as congenital adrenal hyperplasia (CAH). The company’s investigational drug, Crinecerfont, is currently in late-stage clinical trials for this condition.

Business Model

Neurocrine Biosciences operates on a hybrid business model that integrates research and development (R&D), strategic partnerships, and commercialization. The company invests heavily in R&D to discover and develop innovative therapies, leveraging its expertise in neuroscience and endocrinology. Revenue is primarily generated through product sales, licensing agreements, and milestone payments from collaborations with other pharmaceutical companies.

The company’s commercialization strategy focuses on building strong relationships with healthcare providers and patient advocacy groups to ensure broad access to its therapies. Neurocrine also employs a targeted marketing approach to educate physicians and patients about the benefits of its products.

Strategic Direction

Neurocrine Biosciences is committed to expanding its product portfolio and addressing unmet medical needs. The company’s strategic priorities include:

  • Pipeline Expansion: Neurocrine is advancing a robust pipeline of investigational therapies, including treatments for epilepsy, depression, and rare genetic disorders.
  • Global Growth: The company aims to expand its presence in international markets, particularly in Europe and Asia, to reach more patients worldwide.
  • Sustainability Goals: Neurocrine is dedicated to environmental sustainability and corporate responsibility, implementing initiatives to reduce its carbon footprint and promote diversity and inclusion.
  • Digital Innovation: The company is exploring digital health solutions to enhance patient outcomes and streamline clinical trials.

Competitive Landscape

Neurocrine Biosciences operates in a highly competitive biopharmaceutical industry. Key competitors include:

  • Teva Pharmaceuticals: A major player in the neurological disorders market, offering treatments for conditions such as Parkinson’s disease and multiple sclerosis.
  • AbbVie: A partner and competitor, AbbVie develops therapies for endocrine and psychiatric disorders, including endometriosis and depression.
  • Biogen: Focused on neurological diseases, Biogen competes with Neurocrine in areas such as epilepsy and cognitive disorders.
  • Sage Therapeutics: A direct competitor in the psychiatric disorders space, Sage is developing innovative treatments for depression and other mood disorders.

Risk Factors

Like any biopharmaceutical company, Neurocrine Biosciences faces several risks, including:

  • Market Dependence: The company relies heavily on the success of INGREZZA, which accounts for a significant portion of its revenue. Any decline in sales or competition could impact financial performance.
  • Regulatory Challenges: The approval process for new drugs is lengthy and uncertain, posing risks to the company’s pipeline.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers exposes the company to potential disruptions.
  • Intellectual Property: Patent expirations and challenges to intellectual property rights could affect the company’s competitive position.

Recent Developments

Neurocrine Biosciences has made significant strides in recent years, including:

  • FDA Approvals: The company received FDA approval for expanded indications of INGREZZA, broadening its market potential.
  • Clinical Trials: Positive results from late-stage trials of Crinecerfont for CAH and other pipeline candidates.
  • Partnerships: New collaborations with biotech firms to co-develop therapies for rare diseases and neurological conditions.
  • Global Expansion: Launch of INGREZZA in select international markets, marking a milestone in the company’s global growth strategy.

Investment Considerations

Strengths

  • Market Leadership: INGREZZA’s dominance in the tardive dyskinesia market provides a strong revenue base.
  • Robust Pipeline: A diverse portfolio of investigational therapies positions the company for long-term growth.
  • Strategic Partnerships: Collaborations with industry leaders enhance R&D capabilities and market reach.

Risks

  • Revenue Concentration: Heavy reliance on a single product increases vulnerability to market fluctuations.
  • Regulatory and Competitive Risks: Challenges in obtaining drug approvals and competition from other biopharmaceutical companies.
  • High R&D Costs: Significant investment in research and development may impact profitability.

Conclusion

Neurocrine Biosciences, Inc. is a dynamic biopharmaceutical company with a strong focus on addressing unmet medical needs in neurology, endocrinology, and psychiatry. With a market-leading product, a robust pipeline, and strategic partnerships, the company is well-positioned for future growth. However, investors should consider the risks associated with market dependence and regulatory challenges. Overall, Neurocrine’s innovative approach and commitment to patient care make it a compelling player in the biopharmaceutical industry.